| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Prenetics Global Limited$18.64
-0.6 (-3.12%)
F 10Pipeline Score Tools & Services · Commercial
Market Cap
298.37 M
EPS
-4.11
P/E Ratio
-4.31 $
Value Trade
5.06 M
12.14 %
Week
-19.65 %
1 Month
-42.12 %
3 Month
-59.22 %
6 Month
-96.51 %
5 Year
-47.72 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
42.54 K
52 Week Range
3.45 - 23.63
% held by Insiders
24.46 %
% held by Institutions
9.77 %
Enterprise Value
238.56 M
Total Shares
15.29 M
Short %
4.9 %
Float Shares
13.58 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 841 of 913)
Percentile RankPrenetics Global Limited has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRENYSE Content Update: NYSE Partner Reindustrialize Kicks Off Summit from Detroit
The NYSE provided a pre-market update highlighting key developments, including the Dow's potential record growth following a U.S.-Iran deal. Reindustrialize Co-founder Austin Bishop will discuss the Summit aimed at boosting America's industrial sector. Additionally, OpenLoop's new Launchpad solution promises to enhance virtual care compliance for brands.
Read more →PRE▼ -8%on this news
Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue
Prenetics Global Limited reported record Q1 2026 results, achieving $36.0 million in total revenue, driven primarily by IM8's significant performance. IM8 revenue reached approximately $33.8 million, marking a 23.1% increase from the previous quarter and nearly sixfold growth year-over-year. The company raised its full-year revenue guidance for IM8 to between $190 million and $210 million. Despite these gains, Prenetics faced ongoing financial challenges, including a reported operational loss of $8.9 million and notable unrealized losses related to digital asset values.
Read more →PRE▼ -8%on this news
Document Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record $16.7 Million in May, Implying $200 Million in Annualized Recurring Revenue Q1 2026 revenue of $36.0 million with IM8 revenue of $33.
Prenetics has announced its financial results for Q1 2026, reporting a revenue of $36.0 million, which includes $33.8 million from its IM8 health brand. This marks a significant 23.1% increase in IM8 revenue compared to the previous quarter and represents nearly six times year-over-year growth. The company has raised its full-year revenue guidance for IM8, now expecting $190 million to $210 million, driven by strong consumer demand and continuous product expansion. Despite a loss of $23.1 million due to non-cash items, Prenetics remains optimistic about future growth as it improves gross margins and expands internationally.
Read more →PRENYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
AstraZeneca has celebrated its transfer to the NYSE, marking the largest transfer by market capitalization in the exchange's history. This event coincides with a positive market reaction following the May jobs report and a record close for the DOW. CEO Pascal Soriot and CFO Dr. Aradhana Sarin are set to discuss the company's future financial goals in a live interview.
Read more →PREPrenetics Appoints Hudson Leogrande, Founder and CEO of Multi-Billion-Dollar DTC Brand Comfrt, to Board of Directors as IM8 Accelerates TikTok and Meta Expansion
Prenetics Global Limited has appointed Hudson Leogrande, the CEO of the successful DTC brand Comfrt, to its Board of Directors as an independent director. This move is part of Prenetics' strategy to enhance its corporate governance and expand its premium health brand, IM8, particularly through TikTok and Meta platforms. IM8 has demonstrated impressive growth, crossing $100 million in annualized recurring revenue within 11 months, with expectations to reach $250-$300 million by the end of 2026. Leogrande's experience with DTC brands is anticipated to aid in scaling IM8 effectively in the competitive market.
Read more →PREDocument Prenetics Appoints Hudson Leogrande, Founder and CEO of Multi-Billion-Dollar DTC Brand Comfrt, to Board of Directors as IM8 Accelerates TikTok and Meta Expansion Hudson Leogrande is the Founder and CEO of Comfrt
Prenetics has appointed Hudson Leogrande, the CEO of Comfrt, to its Board of Directors as an independent director. This appointment aims to enhance corporate governance as the company aims for significant growth in its IM8 brand. IM8 has seen a rapid increase in annual recurring revenue, projected to reach between $250 million and $300 million by the end of 2026. Leogrande's expertise in direct-to-consumer commerce is anticipated to drive further expansion and efficiency in IM8's marketing strategies through social media platforms.
Read more →PRE▲ +16.9%on this news
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
Hinge Health's shares have surged by 72% since its IPO last year, reflecting strong market performance. CEO Daniel Perez is set to discuss the company's growth in an interview, highlighting the positive trajectory since going public. The NYSE continues to provide updates on market activities and IPO developments.
Read more →PRE▲ +5.9%on this news· ran to +22% by day 3
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
Prenetics Global Limited has announced a multi-year partnership with Jay Shetty, who will serve as the Global Ambassador and shareholder for its IM8 health brand. This partnership marks IM8's first ambassador from outside the sports arena and aims to expand its presence in the wellness market. Shetty has been using IM8's Daily Ultimate Essentials product for nearly a year and has a significant social media following that can help promote health and longevity initiatives worldwide. IM8 expects to achieve revenue between $190 million and $210 million for the year 2026 following impressive growth figures reported in Q1 2026.
Read more →PREDocument Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M-$210M Prenetics records Q1 2026 revenue of $36.0 million
Prenetics Global Limited reported preliminary financial results for Q1 2026, recording revenue of $36.0 million, a substantial year-over-year increase largely driven by its IM8 brand. The company has raised its full-year IM8 revenue guidance to between $190 million and $210 million. Despite positive revenue growth, Prenetics faced an increased operational loss of $8.9 million. The strategic transition to quarterly subscription plans is noted as a key factor in driving revenue growth and customer engagement.
Read more →PREPrenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
Prenetics Global Limited (NASDAQ: PRE) has appointed Brian J. Rosin as the Chief Financial Officer of IM8, aiming to support its rapid expansion. Rosin, a seasoned leader in consumer health and e-commerce finance, is tasked with steering the company's financial strategies as IM8 grows. Currently, IM8 is one of the fastest-growing supplement brands, reported to reach revenues between $190 million to $210 million in 2026. The successful launch and sales in over 40 countries highlight IM8's emerging status in the global health market.
Read more →PREPrenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M
Prenetics Global Limited (NASDAQ: PRE) reported preliminary Q1 2026 results, showcasing a significant revenue increase driven by its IM8 brand, which grew nearly 6x year-over-year. The company raised its full-year IM8 revenue guidance to between $190 million and $210 million. Despite a reported operational loss, the company anticipates continued growth with new product launches and strong international expansion.
Read more →PRENYSE Content Update: Global Medical Response to Go Public After $479 Million IPO
Global Medical Response is set to go public following a $479 million IPO. The company's CEO, Nick Loporcaro, will discuss future plans during its trading debut on the NYSE. The overall market sentiment appears positive, with equities rising after favorable economic reports.
Read more →PRE▲ +8.6%on this newsshared move
NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation
Eli Lilly is set to celebrate its 150th anniversary, marking a significant milestone in its history of scientific innovation. The company's CFO, Lucas Montarce, will participate in a discussion on NYSE Live to share insights from recent earnings and the company's journey. This celebration underscores Eli Lilly's enduring influence in the biopharma sector.
Read more →PREPrenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call
Prenetics Global Limited will announce its Q1 2026 financial results on May 14, 2026, before market open. The earnings conference call will take place at 8:30 a.m. ET, featuring a Q&A session with analysts. The company highlights its successful IM8 brand, which has quickly gained traction in the consumer health market.
Read more →PRENYSE Content Update: HawkEye 360 Soars 31% in Trading Debut
HawkEye 360 made a strong debut on the NYSE, with shares rising 31% following its IPO. The pre-market update indicates a generally positive market sentiment, influenced by recent developments in Iran and a favorable jobs report. Enhanced CEO Maximilian Martin is set to celebrate the company's IPO performance later today.
Read more →PREPrenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
Prenetics Global Limited (NASDAQ: PRE) announced a multi-year partnership with Inter Miami CF, making IM8 the club's exclusive Official Health Supplements Partner. This agreement includes an equity stake in Prenetics, marking a notable first for Inter Miami CF in terms of brand partnerships. IM8 will integrate its health supplements into the routines of Inter Miami players, while also gaining marketing rights and global branding opportunities. The partnership aims to enhance IM8's presence in professional sports and leverage Inter Miami's global fanbase for future growth.
Read more →PRENYSE Content Update: UiPath Celebrates Five-Year Listing Anniversary at NYSE
UiPath marks its five-year anniversary as a publicly listed company on the NYSE. The event includes discussions on market insights and the company's journey since its IPO. Other notable anniversaries include Suburban Propane's 30th listing anniversary. Overall, the market is experiencing positive momentum as investors respond to recent developments.
Read more →PRENYSE Content Update: Defense Tech Company AEVEX to Make Its Public Debut
The New York Stock Exchange (NYSE) provided a pre-market update highlighting positive market trends. Aevex is set to make its public debut, with CEO Roger Wells discussing the company's strategy. Additionally, Madison Air saw a notable increase in its stock price on its first trading day.
Read more →PREPrenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One
Prenetics Global Limited has announced a partnership with Vitamin Angels to tackle malnutrition among vulnerable populations. The collaboration aims to provide essential nutrition to 400,000 pregnant women, infants, and young children in its first year. Vitamin Angels brings extensive experience and infrastructure, having supported over 74 million women and children annually. The partnership represents an extension of IM8’s mission to make quality nutrition accessible, highlighting a commitment to improving global health outcomes.
Read more →PRENYSE Content Update: OpenLoop Health Debuts At-Home Sleep Apnea Test with 98% Accuracy
OpenLoop Health has launched an at-home sleep apnea test with an impressive accuracy of 98%. This development marks a significant step in the company's expansion into sleep diagnostics, in collaboration with Happy Sleep. The announcement was made during a pre-market update by the NYSE, highlighting the company's innovative approach in healthcare.
Read more →PRENYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
The NYSE has issued a pre-market update indicating a rise in equities following news of a potential ceasefire with Iran. The exchange is collaborating with the HumanX AI conference in San Francisco, featuring discussions on transformative technologies. Notably, James Foster from Charles River Laboratories will speak at NYSE Live, while Olympic athlete Mikaela Shiffrin recently marked her successful season at the NYSE.
Read more →PREPrenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership
Prenetics Global Limited has announced a multi-year partnership with NBA Champion Giannis Antetokounmpo, who becomes the first NBA athlete shareholder in a NASDAQ-listed health brand. This collaboration aims to leverage Giannis's extensive social media reach and align with IM8's growth strategy, which has seen rapid revenue growth since its launch. The partnership is expected to enhance IM8's market presence and credibility across various sports.
Read more →PRENYSE Content Update: Koppers to Ring Closing Bell for 20th Listing Anniversary
The New York Stock Exchange (NYSE) announced that Koppers will ring the closing bell to celebrate its 20th anniversary of being listed. This event coincides with a positive market trend, despite ongoing uncertainties in the Middle East. The NYSE also features discussions on agricultural innovations and AI applications in business.
Read more →PRENYSE Content Update: York Space Systems Shoots for the Stars with New Contract
The New York Stock Exchange (NYSE) provided a pre-market update highlighting key developments. York Space Systems' CEO will discuss a new commercial contract during the Taking Stock segment. Additionally, the Digital Health CEO Summit is taking place, featuring discussions among top executives in the digital health sector. Ingram Micro's CFO will also share insights on AI and automation.
Read more →PREPrenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation
Prenetics' IM8 has partnered with Superpower to create a unique system that combines clinical-grade supplementation with comprehensive blood testing. This partnership allows consumers to measure the efficacy of their supplements through a closed-loop system. IM8 subscribers can access Superpower's blood testing services at a significantly reduced price, promoting a proactive approach to health management.
Read more →PREPrenetics to Participate in the 38th Annual ROTH Conference
Prenetics Global Limited (PRE) announced its participation in the upcoming 38th Annual ROTH Conference scheduled from March 22 to March 24, 2026. Key executives, including CEO Danny Yeung, will conduct one-on-one meetings and participate in discussions available via webcast. The company's IM8 brand has achieved significant success, surpassing $100 million in revenue within just 11 months of its launch. IM8 is now available in over 30 countries, emphasizing Prenetics' commitment to advancing consumer health through science-based products.
Read more →PRE▲ +18.1%on this news· ran to +36% by day 3
Prenetics Authorizes $40 Million Share Repurchase Program
Prenetics Global Limited (NASDAQ: PRE) has announced a $40 million share repurchase program, reflecting confidence in its current stock value. The management team has collectively invested approximately $2.75 million in company shares, underlining their commitment. With $164 million in total adjusted liquidity and a zero-debt status, Prenetics is well-positioned to fund growth, particularly in their IM8 brand, which aims for substantial revenue increase in 2026. The repurchase program highlights the board's belief that current share prices do not fully reflect the company's underlying value.
Read more →PREPrenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
Prenetics Global Limited's executives have made a second consecutive round of open market purchases, investing approximately $1.3 million in shares. This follows a prior investment of about $1.45 million, bringing total personal investments to $2.75 million. CEO Danny Yeung emphasized the strong performance of the IM8 brand and the belief that the share price does not reflect the company's progress.
Read more →PREDocument Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million- Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million CEO Danny Yeung makes pe
Prenetics Global Limited announced that its executive leadership team made a second round of open market purchases of company stock, totaling approximately $1.3 million. CEO Danny Yeung personally invested around $750,000 in this round, increasing his prior investment. Together, the leadership has invested about $2.75 million across two post-earnings trading windows. The IM8 brand is experiencing significant growth, with annualized recurring revenue surpassing $100 million within 11 months of launch.
Read more →PRE▼ -8.4%on this news
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
Prenetics Global Limited has launched Daily Ultimate Essentials PRO, a new clinical-grade health supplement featuring enhanced potency and bioavailability. The reformulated product introduces two new flavors, Mango + Passionfruit and Lemon + Orange, while keeping the price unchanged for all customers. The PRO formula incorporates advanced nutritional science, including bioactive vitamin forms for superior absorption.
Read more →PRE▼ -7.7%on this news· ran to -28% by day 3shared move
Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY
Prenetics Global Limited reported record financial results for Q4 and FY 2025, driven by the success of its IM8 brand, which achieved $120 million in annual recurring revenue within just 12 months. The company's revenue surged by 480% year-over-year to $92.4 million. Strategic divestitures have improved liquidity, positioning Prenetics for continued growth, despite facing challenges such as increased costs and ongoing losses.
Read more →PRE▼ -7.7%on this news· ran to -28% by day 3shared move
Document Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Gl
Prenetics Global Limited has successfully completed the sale of its 35% equity stake in Insighta to Tencent for $70 million. This transaction significantly boosts Prenetics' cash resources, resulting in a total adjusted liquidity of $171.1 million, while maintaining zero debt. The company aims to leverage this capital to expedite the global expansion of its IM8 health brand. Financial updates will be presented during their upcoming earnings announcement on February 18, 2026.
Read more →PRE▼ -7.7%on this news· ran to -28% by day 3shared move
Document Prenetics Reports Record Q4 and FY 2025 Results IM8 Achieves $120M ARR 1 in 12 Months, Revenue Surges 480% YoY Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 million I
Prenetics Global Limited reported exceptional financial results for the fourth quarter and full year of 2025, marked by a 480% revenue increase year-over-year, reaching $92.4 million. The standout performer was IM8, achieving $120 million in annual recurring revenue just a year after its launch. The company successfully completed a strategic transformation, divesting several business units to strengthen its financial position, which now boasts approximately $171 million in adjusted liquidity. These results reflect a positive trajectory for Prenetics as it focuses on global expansion within the consumer health sector.
Read more →PREPrenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity
Prenetics Global Limited has completed the sale of its 35% equity interest in Insighta to Tencent for $70 million. This transaction significantly boosts the company's liquidity, bringing total adjusted liquidity to $171.1 million. With zero debt, Prenetics aims to accelerate the global expansion of its IM8 brand, which has shown rapid growth in the consumer health sector.
Read more →PREDocument Prenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Ali
Prenetics Global Limited has appointed Dr. Darshan Shah, a noted expert in longevity medicine, to its Board of Directors, effective February 16, 2026. His extensive experience, including 20,000+ surgeries and leadership of the health optimization brand, Next Health, brings valuable insights to Prenetics’ strategy. Dr. Shah's involvement is expected to bolster both the scientific and commercial capabilities of the company, particularly in advancing its IM8 brand in health and longevity. This strategic move aligns with Prenetics' goals of scaling its offerings and enhancing shareholder value.
Read more →PREPrenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors
Prenetics Global Limited has appointed Dr. Darshan Shah, a prominent expert in longevity medicine, to its Board of Directors as an independent director. Dr. Shah, who has extensive clinical and entrepreneurial experience, is expected to significantly enhance the Board's expertise and contribute to the company's growth strategy, particularly with its IM8 health brand. His background includes over 20,000 surgeries and a successful history of scaling health optimization services, which aligns with Prenetics' commitment to innovate and expand in the health sciences sector.
Read more →PREFormula 1 Phenom Ollie Bearman Joins Prenetics’ IM8 Health as Global Ambassador and Shareholder
Prenetics Global Limited has announced Formula 1 driver Ollie Bearman as its new Global Ambassador and shareholder for its IM8 health brand. Bearman, who has shown impressive performance in his racing career, credits IM8's Daily Ultimate Essentials for enhancing his energy and recovery. This partnership underscores IM8's focus on aligning with elite athletes and its rapid growth in the health supplement market.
Read more →PREPrenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call
Prenetics Global Limited (NASDAQ: PRE) will announce its financial results for Q4 and the full year 2025 on February 18, 2026, before market open. An earnings conference call will follow at 10:00 a.m. ET, including a Q&A session. The company's IM8 brand has achieved significant growth in the health and nutrition sector.
Read more →PREPrenetics Reinforces Strategic Focus on IM8, Divests Europa Business For Up to $13 Million
Prenetics Global Limited has completed the sale of its Europa Sports Partners division for up to $13 million to reinforce its focus on the IM8 brand. The strategic divestiture allows Prenetics to concentrate on scaling IM8, projected to generate revenues of $180 to $200 million in 2026. Alongside this transaction, Prenetics highlighted its strong cash position and previous successful divestiture of ACT Genomics. CEO Danny Yeung noted the necessity of streamlining operations amid the rapid growth of IM8.
Read more →PREDocument Prenetics Reinforces Strategic Focus on IM8, Divests Europa Business For Up to $13 Million Company Continues Portfolio Optimization on the Heels of Successful $72 million ACT Genomics sale Company Maintains Stro
Prenetics Global Limited (NASDAQ PRE) has announced the successful divestiture of its Europa Sports Partners business, valued at up to $13 million, as part of its strategic focus on the IM8 health brand. This move follows a successful $72 million sale of ACT Genomics and allows Prenetics to concentrate resources on scaling IM8, which has seen rapid growth in international markets. The divestiture is expected to improve operating margins starting Q2 2026, while maintaining a strong financial standing with more than $70 million in cash and zero debt.
Read more →PREPrenetics Provides Update on Voluntary Warrant Exchange Program, Reaching 86.7% Participation
Prenetics Global Limited has reported an 86.7% participation in its voluntary warrant exchange program, an increase from 83.4%. This exchange will reduce the total number of outstanding warrants and the potential dilution to shareholders. The company believes this move simplifies its capital structure and enhances the attractiveness of its shares.
Read more →PREDocument Prenetics Provides Update on Voluntary Warrant Exchange Program, Reaching 86.7% Participation CHARLOTTE, N.C.
Prenetics Global Limited announced an update on its voluntary warrant exchange program, achieving 86.7% participation. This program involved the exchange of Class A and Class B warrants for Class C warrants, resulting in a significant reduction of potential dilution from 32.3% to approximately 18.3%. The company believes this increase in participation strengthens the impact of the exchange by simplifying its capital structure and enhancing the investability of its shares. Overall, the warrant exchange aims to improve the financial positioning of Prenetics.
Read more →PREPrenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8
Prenetics Global Limited has announced a strategic shift to focus exclusively on its IM8 brand, ceasing Bitcoin purchases to allocate resources towards this rapidly growing consumer health brand. IM8 has achieved significant revenue milestones, generating over $100 million in annualized recurring revenue within 11 months. The company aims to enhance its operations and expand internationally while maintaining a strong financial position.
Read more →PREDocument Prenetics Announces Update to Capital Allocation Strategy Ceases Bitcoin Purchases to Focus on IM8 Company's Capital and Strategic Focus Now Exclusively Focused on IM8 IM8 FY 2026 Revenue Projected to Reach $180
Prenetics Global Limited has announced a strategic shift in its capital allocation strategy by ceasing Bitcoin purchases to focus exclusively on its consumer health brand, IM8. This decision follows the rapid growth of IM8, which generated over $100 million in annualized recurring revenue within just 11 months since its launch. The company aims to enhance its market position and shareholder value through dedicated investment in IM8's operations, product innovation, and international expansion. Prenetics retains a strong financial foundation, with over $70 million in cash and no debt, to support this strategic direction.
Read more →PRE▼ -6.9%on this news
Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure
Prenetics Global Limited (NASDAQ: PRE) has entered into warrant exchange agreements with holders representing approximately 83.4% of its outstanding Class A and Class B warrants. This voluntary program aims to simplify the company's capital structure and significantly reduce potential future dilution. The exchange will convert these warrants into a new Class C warrant with a lower exercise price, improving long-term investment attractiveness. The company's largest institutional shareholders support this strategic move, reflecting confidence in the revised structure.
Read more →PRE▼ -6.9%on this news
Document Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure CHARLOTTE, N.C.
Prenetics Global Limited has entered into warrant exchange agreements with holders representing approximately 83.4% of its outstanding Class A and Class B warrants. This voluntary program aims to simplify the company's capital structure and reduce potential future dilution. The exchange involves consolidating legacy warrants into a single class, which the company believes will enhance its long-term dilution profile and improve transparency for investors. The exchange reflects strong confidence from major institutional shareholders and is not tied to any immediate financing transactions.
Read more →PRE▲ +8.2%on this news
Document PRENETICS GLOBAL LIMITED Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay, Hong Kong NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on 19 December 2025 To the Shareholders of Prene
Prenetics Global Limited has announced its upcoming Annual General Meeting (AGM) scheduled for December 19, 2025. The meeting will take place at the company's offices in Hong Kong, where shareholders will have the opportunity to discuss company affairs with management. Shareholders must register their intent to attend by December 17, 2025, to be eligible to participate in the meeting. The record date for determining entitled shareholders is set for December 11, 2025.
Read more →PRE▲ +8.6%on this news
Prenetics Announces Upcoming Conference Participation
Prenetics Global Limited announced its participation in two upcoming investor conferences. CEO Danny Yeung will engage in one-on-one meetings at The Benchmark Company's conference on December 4, 2025, and deliver a presentation at Sidoti's Year End Virtual Investor Conference on December 10, 2025. The company continues to demonstrate impressive growth through its IM8 brand.
Read more →PRE▲ +11.2%on this newsshared move
Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million
Prenetics Global Limited announced that its executive leadership team purchased approximately $1.45 million in common stock, demonstrating their confidence in the company's future. The purchases included shares by CEO Danny Yeung and other executives, reflecting a collective belief in the growth of Prenetics and its IM8 brand. The company is also pioneering a Bitcoin treasury strategy.
Read more →PRE▲ +11.2%on this newsshared move
Document Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million CHARLOTTE, N.C.
Prenetics Global Limited announced that its executive team purchased a total of 111,911 shares of the company's stock for approximately $1.45 million. The purchases demonstrate the executives' confidence in Prenetics' long-term vision, particularly regarding its health tech initiatives and Bitcoin treasury strategy. The company's flagship brand, IM8, has quickly grown to $100 million in annual recurring revenue, positioning Prenetics as a leader in health sciences and innovation. These moves reflect a commitment to enhancing shareholder value and portraying optimism about future growth opportunities.
Read more →PRE▼ -9.4%on this news
Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth
Cantor Fitzgerald has maintained its Overweight rating on Prenetics, adjusting the price target to $31 from $32. The report highlights strong unit economics and a forecasted revenue of $217 million by FY2026 as the IM8 brand expands internationally. However, the adjustment reflects valuation model updates due to the planned divestment of the Europa business.
Read more →PREPrenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR[1] by December 2025, Fastest Supplement Brand Growth in Industry HistoryAPAC - EnglishAPAC - Traditional Chinese
Prenetics reported a remarkable 568% year-over-year revenue increase to $23.6 million in Q3 2025, driven by its IM8 brand, which is on track to achieve $120 million in annual recurring revenue by December 2025. The company also announced a successful $44 million equity offering, enhancing its financial position for aggressive growth. Despite a significant adjusted EBITDA loss, Prenetics is optimistic about reaching $300 million ARR by the end of 2026.
Read more →PRE▲ +7.3%on this newsshared move
Prenetics公佈2025年第三季業績創歷史新高；IM8預計在2025年12月前實現1.2億美元的年度經常性收入[1]，成為業界成長最快的保健品品牌 領先的健康科學公司及高端健康長壽品牌IM8的母公司Prenetics Global...
Prenetics Global Limited has announced a significant revenue increase of 568% for the year, reaching $2.36 billion. The company anticipates its product line, IM8, to generate $1.2 billion in annual recurring revenue by December 2025. With a strong customer base and a projected monthly revenue of $2.5 million, Prenetics is positioned for rapid growth in the health and wellness market.
Read more →PREPrenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History
Prenetics Global Limited reported a remarkable 568% year-over-year revenue increase, totaling $23.6 million in Q3 2025. The company’s IM8 brand is on track to achieve $120 million in annual recurring revenue by December 2025, marking the fastest growth in the supplement industry. The company also boasts strong unit economics and a solid financial foundation following a recent equity offering.
Read more →PREDocument Prenetics Reports Record Third Quarter 2025 Results IM8 on Track for $120M ARR 1 by December 2025, Fastest Supplement Brand Growth in Industry History Total Revenue Surges 568% YoY to $23.6 million IM8 Monthly R
Prenetics Global Limited reported record financial results for Q3 2025, with total revenue increasing by 568% year-over-year to $23.6 million. The company's IM8 brand is projected to achieve $120 million in annualized recurring revenue by December 2025, showcasing the fastest growth trajectory in the supplements industry. However, despite these achievements, Prenetics reported an adjusted EBITDA loss of $(2.1) million and a net loss of $(6.8) million for the quarter. The company's financial outlook remains positive, fueled by a recent $44 million equity offering.
Read more →PREPrenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call
Prenetics Global Limited announced it will release its financial results for Q3 2025 on November 10, 2025, before market open. The company will also host its first earnings conference call at 8:30 a.m. ET the same day, which will include a Q&A session. Prenetics is noted for its rapid growth in the health sciences sector, particularly with its IM8 brand.
Read more →PRE▼ -5.6%on this newsshared move
Prenetics’ IM8 Achieves Record $9 Million in Revenue for October, Surpasses $108 Million in Annualized Recurring Revenue 11 Months After Launch
Prenetics Global Limited reported a record $9 million in revenue for October, marking a 32% month-over-month increase. The company achieved approximately $108 million in annualized recurring revenue just 11 months post-launch of its IM8 brand. With a recent $44 million equity offering, Prenetics is positioned for accelerated growth and global expansion, exploring partnerships with top athletes.
Read more →PREPrenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR
Prenetics Global Limited has acquired 100 Bitcoin, increasing its total holdings to 378 BTC. This acquisition follows a successful $44 million equity offering, attracting notable investors. The company reported record growth for its IM8 supplement brand, achieving $100 million in annual recurring revenue within 11 months. Prenetics aims to leverage its strong financial position to accelerate growth and maintain market leadership.
Read more →PREPrenetics CEO Danny Yeung Publishes "The Dual-Engine Revolution" Manifesto: A Blueprint for the Future of Health + Wealth
Prenetics Global Limited, led by CEO Danny Yeung, has published a manifesto titled "The Dual-Engine Revolution," detailing its innovative strategy combining healthcare growth with Bitcoin treasury management. The company has achieved remarkable success with its IM8 supplement brand, reaching $100 million in annual recurring revenue within 11 months. The manifesto outlines the financial resilience provided by their Bitcoin strategy and the projected revenue growth for the upcoming fiscal year.
Read more →PREPrenetics Announces Closing of Approx. $44.0 Million Equity Offering to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
Prenetics Global Limited has successfully closed a public equity offering, raising approximately $44 million. The funds will be utilized for the global expansion of its IM8 brand and for accumulating Bitcoin as part of its dual health and wealth strategy. The company has experienced rapid growth, achieving significant revenue milestones within a short period.
Read more →PRE▼ -6.5%on this newsshared move
Document Prenetics Announces Closing of Approx. $44.0 Million Equity Offering to Fuel IM8's Global Expansion and Bitcoin Treasury Strategy CHARLOTTE, NC
Prenetics Global Limited has successfully closed an equity offering, raising approximately $44 million intended to fuel the global expansion of its health brand IM8 and support its Bitcoin treasury strategy. The offering involved selling Class A ordinary shares and associated warrants, with the proceeds slightly below earlier projections. As a leading innovator in the health sciences sector, Prenetics aims to capitalize on the explosive growth of its health solutions while navigating the complexities of digital asset management.
Read more →PREPrenetics Announces Oversubscribed Approximately $48 Million Equity Offering with Potential for $216 Million in Total Proceeds to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
Prenetics announced an oversubscribed equity offering, raising approximately $48 million, with potential total proceeds of $216 million. The offering is aimed at fueling the global expansion of its supplement brand, IM8, which has rapidly achieved $100 million in annual recurring revenue. The company is also focusing on its Bitcoin treasury strategy, aiming for significant growth in the coming years.
Read more →PRE▼ -22%on this newsshared move
Prenetics Announces $48.0 Million Equity Offering to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
Prenetics Global Limited (NASDAQ: PRE) has announced a successful $48 million equity offering, set to close on October 28, 2025. The company plans to use these proceeds for the global expansion of its IM8 brand and to enhance its Bitcoin Treasury strategy, positioning itself at the intersection of health and digital assets. The public offering includes warrants and shares priced at $16.08, with a focus on financing significant growth following the brand's swift rise in the supplement industry. Forward-looking statements included in the announcement highlight various risks that may impact future performance.
Read more →PRE▼ -22%on this newsshared move
Prenetics Global Limited Announces Proposed Public Offering
Prenetics Global Limited has announced a public offering of its Class A Ordinary Shares and common warrants to support the global expansion of its IM8 brand and to accumulate Bitcoin as part of its innovative strategy. The offering is contingent on market conditions, and details will be filed with the SEC. Prenetics is recognized for its rapid growth in the health sciences sector and its unique position in the cryptocurrency space.
Read more →PREDocument Prenetics Global Limited Announces Proposed Public Offering CHARLOTTE, N.C.
Prenetics Global Limited has announced a proposed public offering of shares and common warrants to fund the global expansion of its flagship brand, IM8, and to build a Bitcoin treasury. The offering is contingent on market conditions, leading to uncertainty about its completion and terms. As a health sciences company co-founded by David Beckham, Prenetics aims to innovate at the intersection of health and digital assets, currently purchasing one Bitcoin daily. However, market volatility and competition present potential risks to its strategies.
Read more →PREPrenetics Global Limited (Incorporated in the Cayman Islands with limited liability) Condensed Consolidated Financial Statements For the six months ended
Prenetics Global Limited has reported its condensed consolidated financial statements for the six months ending June 30, 2025. The company achieved a substantial revenue increase, rising to $32,276, yet it continues to incur significant losses, with an overall loss of $23,743. Factors contributing to these results include increased operating costs and a substantial reduction in cash reserves. Despite a rise in gross profit, the financial health of Prenetics shows areas of concern moving forward.
Read more →PREPrenetics’ IM8 Launches Daily Ultimate Longevity, First Supplement to Target All 12 Hallmarks of Aging
Prenetics Global Limited has launched Daily Ultimate Longevity, the first supplement targeting all 12 hallmarks of aging. This product, part of the IM8 Health brand co-founded by David Beckham, has seen rapid growth, achieving $6.6 million in monthly revenue. The supplement features a proprietary 5-Complex System developed with leading scientists, aiming to redefine longevity science.
Read more →PREPrenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARR
Prenetics Global Limited announced the completion of its $72 million divestment of ACT Genomics to Delta Electronics. This strategic move enhances Prenetics' financial stability, providing over $60 million in cash reserves and positioning its consumer health brand IM8 toward a projected $100 million ARR in its inaugural year. The company has also reported growth in its Bitcoin treasury, now valued at $31.6 million. CEO Danny Yeung emphasized the company's focus on consumer health and transparent management of its digital asset strategy.
Read more →PREPrenetics Announces CEO Danny Yeung Keynote at Token 2049 Singapore
Prenetics Global Limited (NASDAQ: PRE) announced that CEO Danny Yeung will deliver a keynote at Token 2049 in Singapore, discussing the company’s innovative Bitcoin treasury strategy. The presentation will highlight the rapid growth of IM8, Prenetics' supplement brand, projected to surpass $100 million in annual recurring revenue within a year. Prenetics has adopted a disciplined approach to acquiring Bitcoin daily, aiming to strengthen its financial position. The event will gather influential leaders in the crypto and blockchain sectors, emphasizing Prenetics' role in the intersection of health and wealth.
Read more →PREPrenetics 公佈 2025 年第二季度財務業績，IM8 預計於年底達成 1 億美元年度經常性收入目標 領先的健康科學公司 Prenetics Global Limited（納斯達克：PRE）（「Prenetics」或「公司」）今日公佈截至 2025 年 6 月 30 日止第二季度的未經審計財務業績及最新業務進展。 Prenetics 首席執行官兼聯合創辦人 楊聖武 表示：「本季度標誌著...
Prenetics Global Limited (PRE) has announced its financial projections for the second half of 2025, forecasting a revenue increase of 452.1% compared to the previous year. The company aims to achieve annual revenues of $1 billion by 2025, driven by its IM8 Health product line. Prenetics also reported a strong customer acquisition strategy, indicating a solid growth trajectory in the health and wellness sector.
Read more →PREPrenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year's EndAPAC - EnglishAPAC - Traditional Chinese
Prenetics reported impressive financial results for Q2 2025, with a 452.1% increase in revenue year-over-year, reaching $32.3 million. The company anticipates its IM8 brand will achieve $100 million in annual recurring revenue by year-end. Additionally, Prenetics plans to reach break-even by Q1 2026, supported by a robust Bitcoin treasury strategy.
Read more →PRE▲ +13.7%on this newsshared move
Document Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year's End 1 st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million re
Prenetics has reported significant growth in its second quarter financial results for 2025, boasting a 452.1% year-over-year revenue increase to $32.3 million. The company's IM8 health brand is projected to reach $100 million in annual recurring revenue by the end of the year. Despite strong revenue metrics, Prenetics continues to face challenges, including an adjusted EBITDA loss. The company is also pursuing a strategic Bitcoin treasury initiative aimed at enhancing long-term financial stability.
Read more →PRE▲ +16%on this news
Prenetics’ IM8 Congratulates Global Ambassador and Shareholder - World No. 1 Aryna Sabalenka on Defending Her US Open Championship
Prenetics Global Limited congratulates Aryna Sabalenka on successfully defending her US Open title, making her the first woman to do so in over a decade. This victory not only enhances her status with four Grand Slam trophies but also reflects positively on Prenetics and its IM8 supplement brand, which Sabalenka endorses. IM8 has experienced substantial sales growth since its launch in December 2024, bolstered by a viral advertisement that prominently featured the athlete. Sabalenka attributes part of her success to her commitment to health and recovery, supported by IM8 Daily Ultimate Essentials.
Read more →PREUnaudited pro forma condensed financial statements These unaudited pro forma condensed financial statements of Prenetics Global Limited (the "Company") are prepared based on the historical consolidated financial statemen
Prenetics Global Limited has issued unaudited pro forma condensed financial statements reflecting the impact of its divestiture of a 70% stake in ACT Genomics for approximately $46.3 million and recent Bitcoin purchases totaling $20 million. These pro forma statements project financial outcomes as if transactions had occurred earlier, citing the company's significant ongoing losses. This financial reporting aims to provide stakeholders with insights into the company's expected operational adjustments. However, the estimates used are preliminary and may not predict actual future financial performance.
Read more →PREDocument Exhibit. 99.1 RISK FACTORS RELATED TO OUR BITCOIN TREASURY STRATEGY Unless the context otherwise requires, all references to "Prenetics," "we," "us," "our," or the "Company" in risk factors refer to Prenetics Gl
Prenetics Global Limited has implemented a Bitcoin treasury strategy, which allows the company to invest excess cash into Bitcoin. Recently, it completed a $20 million purchase of Bitcoin, acquiring 187.42 BTC. However, the company acknowledges the strategy's associated risks, including market volatility, reliance on financing, and potential counterparty risks, all of which could adversely affect its financial results and market position. The company is also concerned about the changing regulatory landscape surrounding digital assets that complicates its treasury strategy.
Read more →PREPrenetics Global Limited (the Company) Notice of extraordinary general meeting of the shareholders of the Company The Company hereby gives notice that an extraordinary general meeting of the shareholders (the Meeting ) o
Prenetics Global Limited has announced an extraordinary general meeting scheduled for August 1, 2025, to discuss resolutions regarding an increase in the company's authorized share capital from US$50,000 to US$320,000. The meeting will also address necessary filings with the Cayman Islands Registrar of Companies. Additionally, the company plans to file a shelf registration statement with the U.S. SEC for up to US$1 billion to support its Bitcoin treasury strategy and general corporate activities, aimed at enhancing long-term shareholder value. Shareholders are advised to vote on the proposed resolutions during the meeting.
Read more →PRE▲ +23.3%on this news
Document Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction - Bolsters Prenetics' pro-forma cash reserves to approximately US$86 million, and pro-forma cash and short-term a
Prenetics Global Limited has announced the divestment of its ownership in ACT Genomics to Delta Electronics for up to US$71.78 million, significantly enhancing Prenetics' financial standing with pro-forma cash reserves rising to approximately US$86 million. This strategic move allows Prenetics to streamline its focus on high-growth consumer health brands, including IM8, CircleDNA, and Europa, while simultaneously raising its FY2025 revenue guidance to between US$80 to US$100 million. The divestment represents a pivotal step in Prenetics' goal to simplify its business model and optimize resource allocation for future growth.
Read more →PRE▲ +23.3%on this news
Document Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board - Prenetics adopts proven corporate Bitcoin strategy inspired by
Prenetics Global Limited has announced its pioneering Bitcoin treasury strategy, making it the first healthcare company to secure $20 million in Bitcoin. The firm plans to significantly increase its Bitcoin holdings and has appointed Andy Cheung, former COO of OKEx, to its board for oversight on this initiative. With a strong financial position of $117 million in liquidity and a projected revenue of $80-100 million, Prenetics aims to innovate at the intersection of healthcare and blockchain technology. The strategy includes not only holding Bitcoin but also implementing advanced alpha-generating financial strategies.
Read more →PRE▲ +23.3%on this news
Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction
Prenetics Global Limited announced the sale of ACT Genomics to Delta Electronics for up to US$71.78 million, a move aimed at simplifying its business structure and enhancing financial prospects. This divestment is expected to increase Prenetics' cash reserves to approximately US$86 million while allowing the company to focus on its high-growth consumer health brands, including IM8 and CircleDNA. The company has raised its revenue guidance for FY2025, driven by strong performance in its consumer health division. CEO Danny Yeung expressed confidence that ACT Genomics will thrive under Delta's management.
Read more →PRE▲ +23.3%on this news
Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board
Prenetics Global Limited has launched an innovative Bitcoin treasury strategy, marking a significant milestone as the first healthcare company to do so. The company completed a $20 million purchase of Bitcoin and appointed Andy Cheung, former COO of OKEx, to its Board of Directors, enhancing its leadership in this realm. Prenetics' plans include substantial Bitcoin accumulation and the implementation of advanced strategies to maximize returns. With a robust financial position and growing business performance, the company's initiative represents a pioneering approach in the intersection of healthcare and digital assets.
Read more →PRE▲ +5.5%on this news
Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon
Prenetics Global Limited (NASDAQ: PRE) reported impressive financial results for Q1 2025, with revenues soaring by 336.5%, reaching $14.4 million. The company has raised its full-year revenue guidance from $73-$85 million to $80-$100 million, reflecting their strong performance and market momentum. Additionally, Prenetics announced plans to unveil a crypto strategy soon, as part of its innovative treasury management approach. Despite these significant gains, the company reported an increase in adjusted EBITDA losses, highlighting ongoing challenges.
Read more →PRE▲ +5.5%on this news
Document Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, Crypto Strategy Announcement Soon Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics 1 ) Raises full yea
Prenetics Global Limited (NASDAQ PRE) reported significant first quarter results for 2025, revealing a 336.5% increase in revenue, amounting to $14.4 million. The company also raised its revenue outlook for the full year to a range of $80 to $100 million. Notably, its IM8 brand contributed $5.7 million in Q1 and is expected to see continued growth in Q2. Additionally, a new strategic crypto initiative is set to be unveiled soon as part of their innovative treasury approach.
Read more →PRE▲ +5.5%on this news
Document UPDATE - Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, Crypto Strategy Announcement Soon Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics 1 ) Raises
Prenetics Global Limited reported strong financial results for the first quarter of 2025, with revenues up 336.5% year-over-year, reaching $14.4 million, excluding ACT Genomics. The company raised its full-year revenue guidance to $80 - $100 million, reflecting robust momentum in its consumer health initiatives, particularly from IM8. Management expressed confidence in their strategic direction, emphasizing plans for a crypto strategy to enhance capital allocation and shareholder value. With significant cash reserves, Prenetics is well-positioned for ongoing growth and innovation in the healthcare sector.
Read more →PREPrenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market
IM8 Health, co-founded by David Beckham, has expanded its Scientific Advisory Board by adding Dr. Jeremy London and Dr. Amy Shah, both of whom are recognized experts in their respective fields. Their expertise is expected to elevate the company's research and development efforts in health and wellness products. IM8's commitment to innovation is reinforced by the credentials of its SAB members, who have extensive backgrounds in medicine, science, and nutrition. The company's flagship product aims to combine several supplements into one effective solution, aligning with growing consumer demand in the supplements market.
Read more →PREPrenetics to Participate in the 37th Annual ROTH Conference
Prenetics Global Limited (NASDAQ: PRE) announced its participation in the 37th Annual ROTH Conference, scheduled from March 16 to March 18, 2025. The company's CEO Danny Yeung and President of Americas David Vanderveen will host one-on-one meetings with investors. They will also partake in a panel discussion on Longevity and Supplementation during the event. This participation underscores Prenetics' commitment to enhancing consumer and clinical health through innovative strategies.
Read more →PREPrenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 GuidanceAPAC - EnglishAPAC - Traditional Chinese
Prenetics Global Limited reported a significant revenue growth of 93.5% in Q4 2024, totaling $10.5 million, and a year-over-year increase of 40.9% to $30.6 million for the full year. The company projects a revenue of $73 million to $85 million for 2025, driven by the launch of its IM8 Health brand. CEO Danny Yeung highlighted the company's strategic focus on consumer health brands and the positive impact of recent acquisitions.
Read more →PREPrenetics 公布 2024 年第四季度及全年財務業績，並提供 2025 年業績指引 Prenetics Global Limited（納斯達克：PRE）（以下簡稱「Prenetics」或「公司」），作為全球領先的消費者健康科學公司，今日公布截至 2024 年 12 月 31 日的第四季度及全年初步未經審計財務業績，以及最新業務動態。 管理層評論...
Prenetics Global Limited (PRE) announced its financial projections for Q4 2024 and full-year 2025, expecting a revenue increase of 93.5% to approximately 1,050 million TWD in Q4 2025. The company anticipates total revenue for 2025 to range between 7,300 million and 8,500 million TWD, driven by strong growth in its health technology services, particularly through its IM8 Health brand.
Read more →PREDocument Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance Revenue grew 93.5% to $10.5 million in the fourth quarter and 40.9% year-over-year to $30.6 million in 2024 Cash an
Prenetics Global Limited has reported a significant revenue growth of 93.5% in Q4 2024, totaling $10.5 million, and an annual revenue of $30.6 million, marking a 40.9% increase year-over-year. The company has provided guidance for 2025, projecting revenue between $73 million and $85 million, largely driven by the new IM8 Health brand. Despite these gains, Prenetics is anticipating continued losses in adjusted EBITDA as they focus on their consumer health brands. The company is also increasing its cash position by divesting from non-core assets to strengthen its operations in the health sector.
Read more →PRE▲ +6.1%on this news
Prenetics Unveils IM8 to U.S. Consumers with Co-Founding Partner David Beckham
Prenetics has launched its premium supplement brand IM8 in the U.S., co-founded by David Beckham, in a high-profile event in New York City. The two-part launch included sessions featuring wellness advocate Deepak Chopra and discussions with IM8's Scientific Advisory Board. The brand emphasizes a science-backed approach to health and has already garnered attention due to Beckham's involvement and influencer endorsements. IM8's Daily Ultimate Essentials has received NSF certification, adding to its appeal in the competitive health supplement market.
Read more →PREPrenetics’ IM8 Achieves Prestigious NSF Certified for Sport for Daily Ultimate Essentials
Prenetics' IM8 brand, co-founded by David Beckham, has achieved the NSF Certified for Sport® certification for its Daily Ultimate Essentials supplement. This certification signifies that the product meets stringent safety and quality standards, having undergone rigorous testing for banned substances and contaminants. The company emphasizes its dedication to transparency and trust, appealing to both professional athletes and health-focused consumers. IM8 aims to combine premium nutrition with scientific rigor in its offerings.
Read more →PREPrenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium SupplementsAPAC - EnglishAPAC - Traditional Chinese
Prenetics' IM8 has announced a collaboration with Mayo Clinic to develop a new line of premium supplements. This partnership aims to create evidence-based products focusing on nutrition, cellular rejuvenation, and overall wellness. The collaboration combines IM8's innovation with Mayo Clinic's medical expertise, ensuring high standards of efficacy. Initial research is already yielding promising results.
Read more →PREPrenetics 旗下的 IM8 聯手Mayo Clinic，共同研發全新高端營養補充品系列 Prenetics (NASDAQ:PRE) 旗下專注於健康科技的高端營養補充品品牌 IM8，宣佈與Mayo Clinic簽署技術知識協議，共同研發新一代高端補充品。這項合作旨在結合 IM8 的創新技術與 Mayo Clinic 的醫療專長，推動健康與長壽的全新突破。...
Prenetics has announced a collaboration with Mayo Clinic to develop the IM8 health supplement line. This new product aims to leverage advanced scientific research to enhance health outcomes. The IM8 line is set to launch officially on November 18, 2024, and is designed to meet the growing demand for effective health supplements. The partnership emphasizes a commitment to quality and innovation in health technology.
Read more →PRE▲ +15.6%on this news
Document PRENETICS GLOBAL LIMITED Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay, Hong Kong NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on 27 December, 2024 To the Shareholders of Pren
Prenetics Global Limited has announced its Annual General Meeting scheduled for 27 December 2024. The meeting will take place at the company's principal executive offices in Hong Kong, starting at 10:00 am. Shareholders will have the opportunity to discuss company affairs and submit questions. To attend, shareholders must register by 25 December 2024.
Read more →PREPrenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications ServicesAPAC - EnglishAPAC - Traditional Chinese
Prenetics' IM8 has launched a month-long space experiment aboard the ISS, in collaboration with the University of Oxford. The study aims to investigate accelerated aging and longevity by utilizing microgravity to mimic aging processes at the cellular level. This research could lead to significant advancements in understanding age-related diseases and improving healthspan on Earth.
Read more →PRE▲ +13.7%on this newsshared move
Prenetics 的 IM8 聯手牛津大學啟動前沿太空實驗，借助 SpaceX 探索國際太空站上的快速老化與長壽奧秘，由 Space Applications Services 提供支持 Prenetics 的 IM8 欣然宣布，其與牛津大學合作的突破性太空實驗，現已在國際太空站 (ISS) 上全面啟動。這次實驗為期一個月，並得到 Space Applications Services 和 Metavisionaries 的技術支持。任務於 11 月 4 日晚 9 點 29 分由...
Prenetics has successfully launched its IM8 product aboard the International Space Station (ISS) with support from SpaceX. The IM8 aims to enhance human health and longevity through innovative research. This initiative is backed by collaborations with Space Applications Services and Metavisionaries, marking a significant step forward in aging research. The experiment is set to run for one month, focusing on the effects of aging in microgravity.
Read more →PREPrenetics Announces Participation in December Investor Conferences
Prenetics Global Limited, a health sciences company, announced its participation in two investor conferences scheduled for December 2024. The CEO, Danny Yeung, will present at the iAccess Alpha Virtual Best Ideas Winter Conference on December 10, followed by one-on-one meetings on December 11. At the 13th Annual ROTH Deer Valley Event, President David Vanderveen will also conduct one-on-one investor meetings. The company emphasizes its commitment to advancing consumer and clinical health through innovative services and technology.
Read more →PREPrenetics Announces Third Quarter 2024 Financial Results Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results ...
Prenetics Global Limited reported a strong third quarter for 2024, with revenues reaching $7.8 million, a 59.4% increase from the previous year. The company successfully launched its premium supplements brand, IM8Health.com, and secured a $30 million investment from Tencent to support its early cancer detection venture, Insighta. Despite these positive developments, Prenetics continues to face challenges with significant operational losses.
Read more →PREPrenetics公布2024年第三季度財務業績 領先的健康科學公司Prenetics Global Limited（納斯達克：PRE）（以下稱「Prenetics」或「公司」）今日公布截至2024年9月30日的第三季度未經審計財務業績，以及近期業務摘要。 2024年第三季度業績摘要 持續經營業務營收達 778 萬美元，較 2023 年第三季度的 ...
Prenetics Global Limited (PRE) reported a robust financial performance for Q3 2024, achieving a revenue increase of 59.4% year-over-year, totaling $780 million. The company also highlighted a significant rise in operational efficiency and product offerings, particularly with the launch of IM8Health.com. Looking ahead, Prenetics aims to surpass $3,300 million in revenue for the fiscal year 2024, reflecting strong market demand and strategic growth initiatives.
Read more →PREDocument Prenetics Announces Third Quarter 2024 Financial Results Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Inves
Prenetics Global Limited reported a 59.4% increase in revenue for the third quarter of 2024, reaching $7.8 million, driven by operational efficiencies and cost optimizations. The company officially launched its premium supplements brand, IM8Health.com, which has received positive initial customer responses and is shipping to 31 regions. Prenetics also confirmed a strategic investment of $30 million from Tencent to enhance its early cancer detection capabilities through its venture, Insighta. The company maintains an optimistic outlook, aiming to exceed a revenue target of $33 million for the full fiscal year 2024.
Read more →PREPrenetics Announces Third Quarter 2024 Financial Results
Prenetics Global Limited reported substantial financial growth in its third quarter of 2024, with a revenue increase of 59.4% year-over-year to $7.8 million. The launch of IM8Health.com, a new premium supplements brand, has garnered positive customer responses. Strategic investments, particularly a $30 million investment from Tencent in Insighta, have further solidified the company's financial positioning. Prenetics remains optimistic about surpassing a revenue target of $33 million for FY 2024, driven by their expansion efforts in the US market.
Read more →PRENasdaq-Listed Prenetics and David Beckham Officially Launch IM8 Health Prenetics, (NASDAQ: PRE) a leading health sciences company, in partnership with David Beckham, today announced the official launch of IM8. This...
Prenetics has officially launched IM8, a new health and wellness brand co-founded by David Beckham. The brand introduces two products, Daily Ultimate Essentials and Daily Ultimate Longevity, designed to enhance daily health and support healthy aging. IM8 products are now available for purchase online, shipping to 31 countries, with a focus on quality and scientific backing.
Read more →PRE納斯達克公司 Prenetics 與 David Beckham 正式推出 IM8 健康品牌 領先的健康科學公司Prenetics Global Limited（納斯達克：PRE）（以下稱「Prenetics」或「公司」）今日正式宣布，攜手David Beckham 推出全新健康品牌 IM8。IM8 首批推出兩款高端產品—Daily Ultimate Essentials 和 Daily...
Prenetics Global Limited has officially launched its new health brand, IM8, with David Beckham as a prominent partner. The IM8 product line includes Daily Ultimate Essentials and Daily Ultimate Longevity, designed to support daily health and longevity. The products are now available online and aim to provide high-quality nutritional support to consumers worldwide.
Read more →PREPrenetics Announces Participation in the Sidoti Virtual Micro Cap Investor Conference
Prenetics (NASDAQ: PRE) announced its participation in the Sidoti Virtual Micro Cap Investor Conference scheduled for November 13-14, 2024. CEO Danny Yeung and CFO Stephen Lo will present virtually on November 13th at 8:30 a.m. ET, with a link to the webcast available on the company's investor webpage. Additionally, management will offer one-on-one meetings with investors, providing an opportunity for direct engagement.
Read more →PRE▲ +19.1%on this news
Prenetics宣佈騰訊投資Insighta 3,000萬美元，強化 AI 驅動的癌症早期檢測戰略合作 領先的健康科學公司Prenetics Global Limited（納斯達克：PRE）（以下稱「Prenetics」或「公司」）今日宣布，騰訊已向香港早期癌症檢測公司 Insighta 投資了 3,000 萬美元。此項投資使 Insighta 的估值達到 2...
Prenetics Global Limited announced a significant investment of HKD 30 million in Insighta, a company specializing in early cancer detection. This investment is expected to enhance Prenetics' capabilities in the healthcare sector, particularly through the use of AI technology in diagnostics. Following the transaction, Prenetics will hold a reduced stake in Insighta, which may impact its shareholding structure.
Read more →PRE▲ +19.1%on this news
Document Prenetics Announces Tencent's US$30 Million Investment in Insighta, Strengthening Strategic Partnership for AI-Driven Early Cancer Detection Hong Kong
Prenetics Global Limited announced that Tencent has made a strategic investment of $30 million in Insighta, a Hong Kong-based early cancer detection company, valuing Insighta at $200 million. As part of the agreement, Prenetics' ownership in Insighta will decrease from 50% to 35%, while Insighta's co-founders retain their 50% share. The investment will enhance Insighta's ability to develop and commercialize its FRAGMA technology, which focuses on detecting cancer at an early stage through innovative DNA analysis. With Tencent's resources, Insighta aims to improve cancer diagnosis and increase accessibility to early detection methods.
Read more →PRE▲ +19.1%on this news
Prenetics Announces Tencent’s US$30 Million Investment in Insighta, Strengthening Strategic Partnership for AI-Driven Early Cancer Detection
Prenetics Global Limited announced a strategic US$30 million investment from Tencent in Insighta, a company focused on early cancer detection. This investment values Insighta at US$200 million, reducing Prenetics’ stake from 50% to 35%. The partnership aims to enhance cancer detection through Insighta's proprietary FRAGMA technology, which is designed for the non-invasive detection of various cancers. With this funding, Insighta is well-equipped to advance its clinical trials and commercial efforts in cancer diagnostics.
Read more →PRE▲ +19.1%on this news
Prenetics Announces Tencent's US$30 Million Investment in Insighta, Strengthening Strategic Partnership for AI-Driven Early Cancer Detection Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced that Tencent has made a strategic US$30 million investment ...
Prenetics Global Limited announced a strategic US$30 million investment from Tencent in Insighta, reducing Prenetics' stake to 35%. This investment values Insighta at US$200 million and aims to enhance AI-driven early cancer detection through its FRAGMA technology. Insighta is currently conducting clinical trials in China for liver cancer and plans to expand to lung cancer detection.
Read more →PRE▼ -6.9%on this news
Prenetics公布2024年第二季度財務業績 領先的健康科學公司Prenetics Global Limited（納斯達克：PRE）（以下稱「Prenetics」或「公司」）今日公布截至2024年6月30日的第二季度未經審計財務業績，以及近期業務摘要。 2024年第二季度業績摘要 持續經營業務營收達 594 萬美元，低於去年同期的 651...
Prenetics Global Limited (PRE) has announced its financial performance for the second half of 2024, reporting a revenue of 594 million HKD, which is a decrease from 651 million HKD in the previous year. The company is focusing on optimizing operational efficiency and has launched new health products. However, it anticipates challenges in maintaining growth in specific segments.
Read more →PRE▼ -6.9%on this news
Prenetics Announces Second Quarter 2024 Financial Results Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results ...
Prenetics Global Limited reported its second quarter 2024 financial results, revealing a revenue of $5.9 million, down from $6.5 million in Q2 2023. The company achieved a gross margin of 63.4%, significantly improved from the previous year, driven by operational efficiencies. Prenetics is set to launch its IM8 health brand in the U.S. in October and has reaffirmed its revenue target of over $33 million for FY 2024.
Read more →PRE▼ -6.9%on this news
Prenetics Announces Second Quarter 2024 Financial Results
Prenetics Global Limited (NASDAQ: PRE) announced its financial results for the second quarter of 2024, which showed a decrease in revenue from US$6.5 million in Q2 2023 to US$5.9 million. However, the company's gross margin improved significantly to 63.4%, reflecting successful cost optimization strategies. The upcoming launch of its health and wellness brand, IM8, in the U.S. market is highly anticipated, and Prenetics has reaffirmed its revenue target of exceeding US$33 million for the fiscal year 2024. The adjusted EBITDA loss showed improvement, indicating better operational efficiency amidst the changes.
Read more →PRE▼ -6.9%on this news
Document Prenetics Announces Second Quarter 2024 Financial Results Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024 Enters U.S. Health Market in October with IM8, a New Health and Wellness brand Re-affirms
Prenetics Global Limited (NASDAQ PRE) announced its financial results for Q2 2024, revealing a gross margin increase to 63.4% due to cost optimization. The company reported a revenue decline to US$5.9 million but affirmed a revenue target of over US$33 million for FY 2024. Prenetics is set to launch its new health and wellness brand, IM8, in the U.S. this October, bolstered by a recent acquisition that enhances its distribution capabilities. Overall, the company is focused on advancing its strategic initiatives amid ongoing operational losses.
Read more →PREINDEX Page No. Independent Auditor's Report 1-2 Consolidated Financial Statements Balance Sheet 3 Statement of Operations 4 Statement of Members' Equity (Deficit) 5 Statement of Cash Flows 6 Notes to Consolidated Financi
Europa Partners Holdings, LLC has released its consolidated financial statements, showing a net loss of $8,553,628 for the year 2023. Despite some reductions in operating losses, the overall financial position remains concerning, with total liabilities significantly surpassing total assets. The auditor's report confirms the adherence to U.S. GAAP, but indicates substantial doubt about the company's ability to continue as a going concern due to financial deficits.
Read more →PRE▲ +5.5%on this news
Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry
Prenetics Global Limited announced its acquisition of Europa Sports Partners to strengthen its presence in the consumer health and wellness industry. This strategic move is anticipated to generate over $100 million in revenue for the consumer segment by FY2025 and positions Prenetics' new IM8 brand for success. Europa's extensive distribution network and established reputation will aid Prenetics in transitioning to a direct digital distribution model while also establishing a U.S. headquarters in Charlotte, NC. The acquisition is seen as a significant part of Prenetics' overall growth strategy in health and wellness.
Read more →PRE▲ +5.5%on this news
Prenetics宣布收購Europa Sports Partners，策略性擴展至消費者健康與保健市場 領先的健康科學公司Prenetics Global Limited（納斯達克：PRE）（以下稱「Prenetics」或「公司」）欣然宣佈已成功收購全球電商和零售物流供應商 Europa Sports Partners (以下稱「Europa」) 及其子公司 Hubmatrix。這項策略性收購標誌著 ...
Prenetics Global Limited has announced the successful acquisition of Europa Sports Partners, a leading sports nutrition distributor in the U.S. This strategic move is expected to significantly enhance Prenetics' market share and revenue, with projections indicating over $1 billion in consumer sales by 2025. The collaboration with David Beckham is anticipated to further strengthen Prenetics' brand presence in the health and wellness sector.
Read more →PRE▲ +5.5%on this news
Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of...
Prenetics Global Limited has acquired Europa Sports Partners and its subsidiary Hubmatrix, marking a significant step in its expansion into the U.S. consumer health and wellness market. This acquisition is expected to enhance Prenetics' distribution network and drive revenue growth, with projections of over $100 million by FY2025. The partnership with David Beckham for the IM8 brand further strengthens Prenetics' market position.
Read more →PRE▲ +5.5%on this news
Document Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms
Prenetics Global Limited has announced the acquisition of Europa Sports Partners, a significant step towards expanding its presence in the consumer health and wellness industry. With this strategic move, Prenetics aims to generate over $100 million in revenue from its new brand, IM8, by fiscal year 2025. The acquisition also supports a shift to a digital distribution model and establishes U.S. headquarters in Charlotte, North Carolina. Europa, a leading distributor of sports nutrition products, enhances Prenetics' capabilities in the health and wellness market.
Read more →PRE▲ +12.7%on this news
docx-2024x07x11x21x Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham Beckham becomes a strategic investor in Prenetics Beckham and Prenetics are co-founding partners for IM8, a new health and wellne
Prenetics, a NASDAQ health sciences company, has partnered with David Beckham, who becomes a strategic investor and co-founder of a new health and wellness brand called IM8. This collaboration aims to focus on innovative consumer health products, although specific details are yet to be disclosed. Beckham's involvement aligns with Prenetics' goals of enhancing health innovation and accessibility, inspired by the health guidance he has received throughout his life. The partnership underscores both parties' commitment to impacting global health positively.
Read more →PRE▲ +12.7%on this news
Prenetics，納斯達克健康科學公司，宣布與 David Beckham 展開合作 領先的健康科學公司Prenetics Global Limited（納斯達克：PRE）（「Prenetics」或「公司」），驕傲地宣佈前國際足球明星、企業家和慈善家 David Beckham 已成為該公司的戰略夥伴。Prenetics 和 Beckham 將共同合作推出一個名為 IM8...
Prenetics Global Limited has announced a strategic partnership with David Beckham, who will help promote their new health brand IM8. This collaboration aims to enhance Prenetics' presence in the global health market and focus on consumer wellness. Beckham expressed excitement about working with Prenetics to innovate in the health sector.
Read more →PRE▲ +12.7%on this news
Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham Prenetics, (NASDAQ: PRE) a leading health sciences company, is proud to announce that former international footballer, entrepreneur and...
Prenetics has announced a partnership with David Beckham, who becomes a strategic investor and co-founding partner of a new health and wellness brand, IM8. This collaboration aims to develop innovative consumer health products, leveraging Beckham's influence and Prenetics' scientific advancements. CEO Danny Yeung expressed excitement about the transformative potential of this partnership for global health innovation.
Read more →PRE▲ +12.7%on this news
Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham Beckham becomes a strategic investor in Prenetics Beckham and Prenetics are co-founding partners for IM8, a new health and wellness brand Los Angeles
Prenetics (NASDAQ: PRE) announced a partnership with David Beckham, who has become a strategic investor and co-founding partner for a new health and wellness brand called IM8. This collaboration aims to develop innovative consumer health products. Beckham expressed his enthusiasm about working with Prenetics, emphasizing the importance of accessible health and wellness solutions. Danny Yeung, CEO of Prenetics, noted that Beckham's involvement marks a transformative era for the company in global health innovation.
Read more →PRE▼ -7.1%on this news
Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors
Prenetics Global Limited has appointed Kathryn M. Henry and David Vanderveen as independent directors to its Board of Directors. This decision is highlighted by CEO Danny Yeung as a strategic move to enhance shareholder value during a pivotal period of the company's expansion into consumer health and wellness. Both new board members have significant experience in their respective sectors, aligning well with Prenetics' goals. Their contributions are anticipated to impact Prenetics’ market position positively.
Read more →PREPrenetics Announces First Quarter 2024 Financial Results Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results ...
Prenetics Global Limited reported a strong financial performance for Q1 2024, with a 30.2% increase in revenue and a remarkable 159.8% rise in gross profit compared to the same quarter last year. The company is strategically pivoting towards the U.S. consumer healthcare market, reaffirming its revenue projections for 2024. Despite these positive developments, Prenetics continues to face operational losses and is focused on advancing its early cancer detection venture, Insighta.
Read more →PREPrenetics Announces First Quarter 2024 Financial Results
Prenetics Global Limited (NASDAQ: PRE) reported a strong financial performance for the first quarter of 2024, with a revenue increase of 30.2% and a gross profit growth of 159.8% year-over-year. The company reaffirmed its revenue target for 2024 between US$33 million and US$36 million while focusing on expanding its presence in the U.S. consumer healthcare market. CEO Danny Yeung highlighted the company's solid growth trajectory and the establishment of dual headquarters in the U.S. to maximize opportunities. Additionally, Prenetics' early cancer detection joint venture, Insighta, demonstrated promising initial results, setting the stage for a future clinical trial.
Read more →PREDocument Prenetics Announces First Quarter 2024 Financial Results First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healt
Prenetics Global Limited (NASDAQ PRE) has reported its first quarter 2024 financial results, indicating a revenue increase of 30.2% and a gross profit surge of 159.8% compared to the prior year. The company reaffirms its revenue guidance for 2024, expecting between US$33 million and US$36 million. CEO Danny Yeung emphasized the company's strategic realignment towards the U.S. consumer healthcare market, which aims to broaden accessibility to science-based health solutions. Prenetics also confirmed its early cancer detection venture, Insighta, is progressing to clinical trials.
Read more →PREPrenetics公布2024年第一季度財務業績 領先的基因組學驅動的健康科學公司Prenetics Global Limited（納斯達克：PRE）（「Prenetics」或「公司」）今日公布截至2024年3月31日的第一季度未經審計財務業績，以及近期業務摘要。 2024年第一季度之財務摘要...
Prenetics Global Limited (PRE) announced a 30.2% increase in revenue for the first quarter of 2024 compared to the previous year. The company is focusing on expanding its presence in the U.S. healthcare market, particularly in consumer health and early detection services. Despite previous challenges, Prenetics is optimistic about its growth trajectory and aims to enhance its service offerings.
Read more →PREPrenetics Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
Prenetics Global Limited (NASDAQ: PRE) has engaged MZ Group to enhance its investor relations and financial communications across key markets. The collaboration aims to improve the company's visibility and highlight its innovative contributions to health and wellness, particularly in cancer detection and treatment. CEO Danny Yeung emphasized the organization's strong financial position, commitment to innovation, and upcoming growth catalysts, while also acknowledging the challenges associated with executing its strategic initiatives. The partnership with MZ Group is expected to facilitate better communication with stakeholders in the investment community.
Read more →PREPrenetics公布2023年第四季度及全年財務業績 領先的基因組學驅動的健康科學公司Prenetics Global Limited（納斯達克：PRE）（「Prenetics」或「公司」）今日公布截至2023年12月31日止第四季度及全年的未經審計財務業績，以及近期業務摘要。 財務摘要...
Prenetics Global Limited (PRE) announced its financial results for Q4 2023 and the full year, showcasing a remarkable revenue growth of 65.2% year-over-year. The company achieved its first EBITDA positive result in December 2023, signaling a turnaround in its financial health. Looking ahead, Prenetics anticipates continued growth, projecting revenues between 3,300 million to 3,600 million HKD for 2024.
Read more →PREPrenetics Announces Fourth Quarter and Full Year 2023 Financial Results Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited...
Prenetics Global Limited reported significant financial growth for 2023, with revenues increasing by 65.2% year-over-year. Both of its business units achieved profitability for the first time, and the company is optimistic about future revenue projections of $33 million to $36 million for 2024. Despite a net loss of $62.7 million, the company maintains a strong cash position and is preparing for further clinical trials in early cancer detection.
Read more →PREDocument Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results
Prenetics Global Limited announced its financial results for Q4 and the full year 2023, showcasing a substantial revenue increase of 65.2% year-over-year. Both ACT Genomics and CircleDNA units achieved profitability for the first time, contributing to an adjusted EBITDA loss of US$24.8 million for the year. The company highlighted its strong cash position of US$93.7 million and positive outcomes from a significant clinical trial with its Insighta venture in early cancer detection. Looking ahead, Prenetics is optimistic about future revenue projections and potential opportunities in the consumer healthcare market.
Read more →PREPrenetics Announces Fourth Quarter and Full Year 2023 Financial Results
Prenetics Global Limited reported a strong financial performance for 2023, highlighting a 65.2% increase in revenue to US$21.7 million. Both its business units, ACT Genomics and CircleDNA, achieved profitability for the first time. Additionally, a successful 500-person clinical trial for cancer detection has been completed, with results expected to be published in late 2024. Despite these positives, the company showed a significant adjusted net loss for the year, amounting to US$(28.4) million.
Read more →PRE▲ +6.1%on this news
Prenetics宣佈與Metavisionaries簽署戰略投資和為期五年的研究合作諒解備忘錄，在國際空間站展開研發工作 基因組學驅動的領先健康科學公司Prenetics Global Limited（納斯達克股票代碼：PRE）宣佈，該公司已經簽署了一份諒解備忘錄(MOU)，對Metavisionaries進行戰略投資，並與Metavisionaries 旗下的Metaspace Venture及其合作夥伴Space ...
Prenetics Global Limited has announced a collaboration with Metavisionaries to enhance research in space health technologies. This partnership includes a memorandum of understanding (MOU) and aims to leverage expertise from NASA scientists. The first research phase is scheduled for the fourth quarter of 2024, focusing on advancements in space exploration and health. The collaboration is expected to drive innovation in the field of space health.
Read more →PREPrenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station
Prenetics Global Limited has entered into a Memorandum of Understanding (MOU) with Metavisionaries for a strategic investment and a five-year research collaboration focusing on health advancements in space. The initial project will investigate accelerated aging due to the zero-gravity environment aboard the International Space Station (ISS), with the first research cube expected to launch in Q4 2024. The partnership includes notable figures from NASA, enhancing Prenetics’ scientific efforts. The UAE Space Agency supports this initiative as a significant contribution to the space ecosystem and scientific innovation.
Read more →PREPrenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station Prenetics Global Limited (NASDAQ:PRE), a leading genomics-driven health sciences company, announces the signing of a Memorandum of Understanding...
Prenetics Global Limited has signed a Memorandum of Understanding with Metavisionaries for a strategic investment and a five-year research collaboration. The initial project will focus on accelerated aging in space, with research conducted in partnership with the University of Oxford. The inaugural research cube is set to be sent to the International Space Station in late 2024. This collaboration aims to leverage space exploration for health advancements on Earth.
Read more →PREPrenetics Announces Third Quarter 2023 Financial Results
Prenetics Global Limited announced its financial results for Q3 2023, highlighting progress in its transformation and the completion of a reverse stock split. The company is optimistic about growth opportunities in its consumer health and oncology business units, supported by a solid cash position. CEO Danny Yeung emphasized their commitment to developing innovative solutions like Presight for cancer detection. The announcement indicates an overall positive outlook for the company's growth trajectory and value delivery.
Read more →PREPrenetics公佈2023年三季度財務業績 領先的基因組學驅動的健康科學公司Prenetics Global Limited（納斯達克：PRE）（「Prenetics」或「公司」）今日公布截至2023年9月30日的第三季度財務業績，以及近期業務摘要。 2023年第三季度之財務摘要 持續營運收入為 490 萬美元...
Prenetics Global Limited (PRE) announced its third-quarter financial results for 2023, reporting a steady revenue of 490 million HKD. The company highlighted its ongoing investments in operational capabilities and expressed optimism about future growth despite facing stock performance fluctuations. Recent collaborations and product developments are expected to bolster its market presence.
Read more →PREPrenetics Announces Third Quarter 2023 Financial Results Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial...
Prenetics Global Limited reported its financial results for Q3 2023, showing a revenue of $4.9 million but an adjusted EBITDA loss of $(6.4) million. The company completed a reverse stock split to comply with NASDAQ listing requirements and launched a new genomic test through ACT Genomics. Despite a strong cash position, Prenetics faces ongoing restructuring challenges and significant quarterly losses.
Read more →PRE▲ +5.9%on this news
Prenetics Global Limited Announces Reverse Stock Split
Prenetics Global Limited is implementing a reverse stock split that will take effect on November 14, 2023, after acceptance by Nasdaq. This move is intended to ensure compliance with NASDAQ's minimum $1.00 per share requirement. The split will consolidate shares held by shareholders and adjust the number of shares available through stock options and warrants accordingly. Despite the potential for increased volatility in trading, the company continues to focus on advancing its genomic health solutions and multi-cancer detection technologies.
Read more →PREPrenetics Announces Second Quarter 2023 Financial Results Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial...
Prenetics Global Limited reported its financial results for Q2 2023, highlighting a revenue of US$5.7 million and a significant joint venture with Prof. Dennis Lo focused on early cancer detection. The company is optimistic about its future, emphasizing improvements in operational efficiency and promising clinical trial data. However, it continues to face substantial losses and negative adjusted EBITDA.
Read more →PREPrenetics Announces Second Quarter 2023 Financial Results
Prenetics Global Limited (NASDAQ: PRE) has reported its financial results for Q2 2023, showcasing a commitment to transformative growth. CEO Danny Yeung highlighted significant investments in early cancer detection technologies and a well-defined business strategy focused on prevention, early detection, and targeted therapy. The company is set to introduce innovative products, including Presight for lung and liver cancers by 2025. Despite the optimism, the report contains forward-looking statements, suggesting an intent to address inherent industry risks.
Read more →PREA World's First: The Miss Hong Kong Pageant 2023 Unveiled Contestants' CircleDNA Results Live on Television In a move that had never been seen before, marrying beauty with science, the Miss Hong Kong Pageant 2023, which just aired on TVB, had set out to...
The Miss Hong Kong Pageant 2023 made history by unveiling contestants' DNA results live on television, a first in beauty pageants. This innovative collaboration with CircleDNA aimed to redefine beauty standards by highlighting the importance of genetic profiles alongside physical attributes. Contestants shared diverse ancestral backgrounds and showcased unique talents, promoting a broader understanding of beauty.
Read more →PREPrenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture Insighta for Breakthrough Multi-Cancer Early Detection Screening Company will Host Conference Call to Discuss the Transaction on J
Prenetics and Prof. Dennis Lo have formed a joint venture named Insighta, aimed at developing groundbreaking multi-cancer early detection screening technology. The US$200 million investment marks one of the largest private life sciences deals in Hong Kong history. Insighta, leveraging advanced research from the Centre for Novostics, aims to initiate clinical trials with its first test, Presight, in early 2024, focusing on liver and lung cancer. The venture hopes to significantly enhance early cancer detection and expand screening accessibility across Asia, beginning in 2025.
Read more →PRE▲ +8%on this news
Prenetics Announces First Quarter 2023 Financial Results
Prenetics Global Limited announced its financial results for the first quarter of 2023, indicating a focus on advancing its consumer health and clinical testing strategies. The company plans to launch innovative products within its CircleDNA and ACT Genomics platforms by the end of the year. CEO Danny Yeung is optimistic about the impact of new leadership, particularly Joel Neoh, in driving growth towards a leading consumer health business. Prenetics aims to integrate genetics into healthcare for better early cancer detection and personalized solutions.
Read more →PREPrenetics Announces Fourth Quarter and Full Year 2022 Financial Results New Business Strategy Focused on Precision Oncology
Prenetics Global Limited announced its fourth-quarter and full-year financial results for 2022, revealing a strategic shift back to its core genomics business with a focus on precision oncology. The company highlighted its successful processing of over 28 million COVID-19 tests during the pandemic and is now investing in its oncology product pipeline, specifically targeting early cancer detection. Notably, Prenetics acquired ACT Genomics, receiving FDA clearance for a significant genomic profiling test for solid tumors. Despite reporting a net loss due to restructuring and non-recurring items, the company remains positive about its growth potential.
Read more →PREPrenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
Prenetics Global Limited has announced the establishment of a new Scientific Advisory Board (SAB) to drive its business strategy in precision oncology. The SAB will consist of distinguished experts in oncology and genomics who will provide strategic guidance on the development of Prenetics' diagnostic cancer genomics. Notably, the board will be chaired by Prof. Tony Mok, who has a strong background in lung cancer research. This initiative signals Prenetics' commitment to enhancing early cancer detection and treatment methods.
Read more →PREPrenetics to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Prenetics Global Limited (NASDAQ: PRE) announced its virtual participation in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference scheduled for February 14-16, 2023. The company, known for its genomic and diagnostic testing services, aims to enhance health accessibility worldwide. Founded in 2014, Prenetics operates in multiple countries and offers various health-testing services, including consumer genetic tests and COVID-19 testing. With management led by Danny Yeung, Prenetics is positioned as a leader in decentralized healthcare solutions.
Read more →PRE▼ -5.5%on this news
Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics
Prenetics Global Limited has appointed Dr. Bayju Thakar as the new CEO of Prenetics EMEA. This leadership change is strategic, aimed at leveraging Thakar's extensive experience in healthcare to enhance Prenetics' operations in the UK and EMEA markets. Thakar, a co-founder of UK’s largest telehealth business, is expected to significantly contribute to the growth of Prenetics by focusing on a variety of healthcare opportunities, including personalized cancer diagnostics and IVF services. The company aims to strengthen its position in healthcare while continuing to innovate in genomic and diagnostic testing.
Read more →PRE▲ +22%on this news
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors - Prenetics has completed the majority st
Prenetics Global Limited's subsidiary, ACT Genomics, has achieved FDA clearance for ACTOnco, a comprehensive genomic profiling test specifically for all solid tumors. This marks a significant milestone as ACT Genomics becomes the first Asia-based company to receive such approval, enhancing personalized cancer care in the region. The test is designed to support healthcare professionals in making informed clinical management decisions by offering insights into the genetic aspects of tumors. This development could lead to increased access to precision medicine and potential reimbursement options for patients in Asia.
Read more →PRE▲ +17.1%on this news
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology - Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic prof
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology LONDON AND HONG KONG, December 16, 2022 Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that it is acquiring a majority
Read more →PREPrenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index LONDON AND HONG KONG, November 30, 2022 Prenetics Global Limited (NASDAQ: PRE) ( Prenetics or the Company ), a global leader in genomic and diagnostic testing, today an
Read more →PREPrenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance LONDON AND HONG KONG, November 10, 2022 Prenetics Global Limited (NASDAQ: PRE) ( Prenetics or the Company ), a global leader in genomic and diagnostic testing,
Read more →PRE▲ +11.8%on this news
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook Revenue of US$51.7 million in the second quarter of 2022 Loss from operations of US$(17.9) million and adjusted EBITD
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook AND HONG KONG, September 9, 2022 Prenetics Global Limited (NASDAQ: PRE) ( Prenetics or the Company ), a global leader in genomic and diagnostic testing, today announced its un
Read more →PREPrenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker "PRE."
Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker "PRE." LONDON AND HONG KONG, June 6, 2022 - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic test
Read more →PRE▼ -26.4%on this news
Prenetics Rings the Opening Bell and Debuts
Prenetics Rings the Opening Bell and Debuts Prenetics becomes the first Hong Kong unicorn to list on Nasdaq and its shares began trading on May 18 under ticker "PRE" At Least US$260M of Proceeds from the Business Combination, Cash and Trade Receivables to Support Prenetics G
Read more →PREPrenetics Rings the Opening Bell and Debuts on Nasdaq
Prenetics becomes the first Hong Kong unicorn to list on Nasdaq and its shares began trading on May 18 under ticker “PRE” At Least US$260M of Proceeds from the Business Combination, Cash and Trade Receivables to Support Prenetics Growth Proceeds will allow Prenetics to continue
Read more →Competitive Position
How PRE ranks across every disease it competes inCompetitive Position is a premium feature
See how PRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial